

Contents

New Antisteroidal Agents, Enzyme Inhibitors, and New Treatment Modalities

- 1 Ten Years of Tamoxifen in Breast Cancer: A Review
J. S. Patterson
- 7 Adrenal Steroids Exert Potent Estrogenic Action in Both Normal
and Cancer Tissue
*F. Labrie, R. Poulin, J. Simard, J.-F. Hubert, P. Spinola, and
B. Marchetti*
- 17 Total Androgen Blockade Versus Orchiectomy in Stage D
Prostate Cancer
*J. M. Brisset, C. Bertagna, J. Fiet, A. de Géry, M. Hucher,
J. M. Husson, D. Tremblay, and J. P. Raynaud*
- 31 RU 38486, A Progestin and Glucocorticoid Antagonist in the
Treatment of Experimental Pituitary Tumors
S. W. J. Lamberts
- 39 Mifepristone in Treatment of Experimental Breast Cancer in Rats
G. H. Bakker, B. Setyono-Han, F. H. de Jong, and J. G. M. Klijn
- 47 Antiproliferative Effect of Progestins and Antiprogestins in
Human Breast Cancer Cells
*F. Vignon, S. Bardon, D. Chalbos, D. Derocq, P. Gill, and
H. Rochefort*
- 55 First Clinical Trial on the Use of the Anti-Progestin RU486 in
Advanced Breast Cancer
*T. Maudelonde, G. Romieu, A. Ulmann, H. Pujol, J. Grenier,
S. Khalaf, G. Cavalie, and H. Rochefort*
- 61 Steroid Receptors in Cerebral Tumours: Possible Consequence
for Endocrine Treatment?
*M. A. Blankenstein, G. Blaauw, J. W. van't Verlaat,
C. van der Meulen-Dijk, and J. H. H. Thijssen*
- 71 Current Status of Aromatase Inhibitors for Treatment of Breast
Cancer: New Perspectives
R. J. Santen

- 81 Clinical Studies with 4-Hydroxyandrostenedione in Breast Cancer Patients
R. C. Coombes, T. J. Powles, P. E. Goss, D. Cunningham, G. Hutchison, M. Dowsett, and A. M. H. Brodie
- 89 Second Line Endocrine Therapy in Advanced Breast Cancer. A Randomized Phase II Study, Comparing Aminoglutethimide Plus Hydrocortisone Versus Medroxyprogesterone Acetate Versus Trilostane Plus Hydrocortisone Versus Hydrocortisone: An E.O.R.T.C. Study
C. Rose, H. T. Mouridsen, J. Wildiers, R. Paridaens, R. Sylvester, and N. Rotmensz
- 99 Sex-Steroid Receptors and Antisteroidal Agents in the Treatment of Pancreatic Adenocarcinoma
P. J. Johnson and T. P. Corbishley
- 105 Aminoglutethimide in the Management of Prostatic Cancer: A Review
M. R. G. Robinson
- 111 Ketoconazole in the Treatment of Prostatic Cancer
L. Denis, C. Mahler, and R. De Coster
- 119 A Study of the Role of Additional Androgen Depletion for Primary Therapy of Patients with Advanced Local or Metastatic Carcinoma of the Prostate
G. Williams, E. A. Kiely, R. Kapadia, A. Doble, H. Ware, and A. Timoney
- 127 The Use of Synergistic Hormonal Combinations in the Treatment of Advanced Prostatic Cancer: Cyproterone Acetate Plus Minidose Diethylstilbestrol
S. L. Goldenberg, N. Bruchovsky, P. S. Rennie, C. M. Coppin, and E. M. Brown

Progestins and Hyperprolactinemia

- 135 Hormonal Aspects and Treatment of Endometrial Carcinoma
J. A. Wijnen
- 145 Alternating and Combined Treatment with Tamoxifen and Progestins in Postmenopausal Breast Cancer
J. Alexieva-Figusch, F. H. de Jong, S. W. J. Lamberts, A. S. T. Planting, H. A. van Gilse, M. A. Blankenstein, J. Blonk-v. d. Wijst, and J. G. M. Klijn

- 157 Prolactin Receptors in Breast Cancer: Importance of the Membrane Preparation
M. L'Hermite-Balériaux, S. Casteels, and M. L'Hermite
- 167 Prolactin and Breast Cancer
P. F. Bruning
- 175 The Prognostic Significance of Hyperprolactinaemia in Breast Cancer
M. Dowsett, G. E. McGarrick, A. L. Harris, R. C. Coombes, I. E. Smith, and S. L. Jeffcoate
- 183 Medroxyprogesterone Acetate High-Dose (MPA-HD) Versus MPA-HD Plus Bromocriptine in Advanced Breast Cancer: Preliminary Results of a Multicenter Randomized Clinical Trial
L. Dogliotti, G. Robustelli della Cuna, F. Di Carlo, and BROMPA Italian Cooperative Group

Luteinizing Hormone Releasing Hormone
Analogues in Cancer Treatment

PROSTATE CANCER

- 195 Effects of Long-Term Treatment with the LHRH-Analogue Buserelin on the Pituitary-Testicular Axis in Men with Prostatic Carcinoma
F. H. de Jong, F. H. Schroeder, M. T. W. T. Lock, F. M. J. Debruyne, H. J. de Voogt, and J. G. M. Klijn
- 203 Pharmacokinetics of LHRH Agonists in Different Delivery Systems and the Relation to Endocrine Function
J. Sandow, H. R. Seidel, B. Krauss, and G. Jerabek-Sandow
- 213 Treatment of Hormone-Responsive Rat Mammary and Prostate Tumours with "Zoladex" Depot
B. J. A. Furr
- 225 Long-Term Treatment with the LHRH Agonist Buserelin in Metastatic Prostatic Cancer. Two Phase II Studies Including Buserelin Plus Cyproterone Acetate
F. H. Schroeder, T. M. T. W. Lock, P. J. Carpentier, D. R. Chadha, F. M. J. Debruyne, F. H. de Jong, J. G. M. Klijn, A. W. Matroos, and H. J. de Voogt

- 235 Endocrine and Clinical Evaluation of 107 Patients with Advanced Prostatic Carcinoma Under Long-Term Pernal Buserelin or Intramuscular Decapeptyl Depot Treatment
G. H. Jacobi, U. K. Wenderoth, W. Ehrental, H. v. Wallenberg, H.-W. Spindler, U. Engelmann, and R. Hohenfellner
- 249 Pharmacodynamics, Pharmacokinetics and Bioavailability of the Prolonged LH-RH Agonist Decapeptyl-SR
J. Happ, H. Schultheiss, G. H. Jacobi, U. K. Wenderoth, K. Buttenschön, K. Miesel, H. Spahn, and G. Hör
- 255 Clinical Results with the Depot Preparation of Zoladex in Prostate Cancer
F. M. J. Debruyne, E. H. J. Weil, P. Fernandez del Moral, and the Dutch South-Eastern Cooperative Urological Group
- 273 Use of LH-RH Analogs for the Treatment of Prostate Cancer: Combination Therapy and Direct Effects
A. V. Schally and T. W. Redding
- 281 Studies with Nafarelin and a Long-Acting LHRH Antagonist
B. H. Vickery, G. I. McRae, L. M. Sanders, P. Hoffman, and S. N. Pavlou
- 291 The Importance of Combination Therapy with Flutamide and Castration (LHRH Agonist or Orchiectomy) in Previously Untreated as Well as Previously Treated Patients with Advanced Prostate Cancer
F. Labrie, A. Dupont, A. Bélanger, M. Giguère, J. P. Borsanyi, Y. Lacourcière, J. Emond, G. Monfette, and R. Lachance
- 301 Leuprolide Versus Diethylstilbestrol for Metastatic Prostatic Cancer
L. J. Swanson and M. B. Garnick
- 309 Comparative Studies with LHRH Agonists
H. J. de Voogt

BREAST AND OVARIAN CANCER

- 315 LH-RH Agonist: Breast and Prostate Cancer
G. Mathé, R. Keiling, G. Prévot, M. L. Vo Van, J. Gastiaburu, J. M. Vannetzel, R. Despax, C. Jasmin, F. Lévi, M. Musset, D. Machover, P. Ribaud, and J. L. Misset

- 321 LHRH Agonist Treatment of Breast Cancer: A Phase II Study in the U.S.A.
H. A. Harvey, A. Lipton, and D. T. Max
- 331 The British Experience with the LH-RH Agonist Zoladex (ICI 118630) in the Treatment of Breast Cancer
R. I. Nicholson, K. J. Walker, A. Turkes, J. Dyas, K. E. Gotting, P. N. Plowman, M. Williams, C. W. Elston, and R. W. Blamey
- 343 Long-Term LHRH-Agonist (Buserelin) Treatment in Metastatic Premenopausal Breast Cancer
J. G. M. Klijn and F. H. de Jong
- 353 LHRH Agonist Treatment in Ovarian Cancer
S. Kullander, A. Rausing, and A. V. Schally

DIRECT EFFECTS OF LHRH ANALOGS

- 357 Direct Inhibition of Human Breast Cancer Cell Growth by an LHRH Agonist
W. R. Miller, W. N. Scott, H. M. Fraser, and R. M. Sharpe
- 369 Direct Effects of LHRH Analogs on Breast and Prostatic Tumor Cells
J. A. Foekens, M. S. Henkelman, J. Bolt-de Vries, H. Portengen, J. F. Fukkink, M. A. Blankenstein, G. J. van Steenbrugge, E. Mulder, and J. G. M. Klijn

Growth Factors

- 381 Mechanisms of Estrogenic and Antiestrogenic Regulation of Growth of Human Breast Carcinoma
M. E. Lippman, R. B. Dickson, E. P. Gelmann, C. Knabbe, A. Kasid, S. Bates, and S. Swain
- 407 A 52-K Estrogen-Induced Protease Secreted by Breast Cancer Cells with Autocrine Mitogenic Activity
H. Rochefort, F. Capony, G. Cavalié, M. Chambon, G. Freiss, M. Garcia, M. Morisset, and F. Vignon
- 415 Epidermal Growth Factor Receptors in Primary Human Breast and Bladder Cancer: Relation to Tumour Differentiation, Invasion, and Patient Survival
A. L. Harris, J. R. C. Sainsbury, K. Smith, D. E. Neal, R. R. Hall, and J. R. Farndon

Somatostatin Analogs and Cancer

- 425 Possible Role of Gastro-Intestinal Hormones in Gastric and Pancreatic Carcinogenesis
C. B. H. W. Lamers
- 431 Somatostatin Analogs in the Treatment of Various Experimental Tumors
A. V. Schally, T. W. Redding, R. Cai, J. I. Paz, M. Ben-David, and A. Comaru-Schally
- 441 Somatostatin Analog Treatment of Pituitary Tumors
S. W. J. Lamberts
- 451 Somatostatin Analogue Treatment of Endocrine Tumours
S. R. Bloom
- 459 Effects of Somatostatin Analog (Sandostatin) Treatment in Experimental and Human Cancer
J. G. M. Klijn, B. Setyono-Han, G. H. Bakker, M. S. Henkelman, H. Portengen, and J. A. Foekens

Hormones as Stimulatory Agents of Tumor Cell Growth in the Treatment of Cancer

- 469 Hormonal Manipulation of Tumor Cells in Combination with Chemotherapy
C. K. Osborne
- 477 Chemotherapy with Estrogenic Recruitment in Breast Cancer: Experimental and Clinical Studies
R. J. Paridaens, R. Kiss, Y. de Launoit, G. Atassi, J. G. M. Klijn, A. Clarysse, N. Rotmentz, and R. J. Sylvester
- 487 Cytokinetic Studies and Treatment Results of Estrogens Followed by Chemotherapy in Locally Advanced and Metastatic Human Breast Cancer
P. F. Conte, A. Rubagotti, P. Pronzato, A. Alama, D. Amadori, G. Canavese, F. Carnino, A. Catturich, M. G. Daga, R. De Micheli, E. Di Marco, G. Gardin, P. Gentilini, A. Jacomuzzi, R. Lionetto, C. Monzeglio, C. Mossetti, A. Nicolin, R. Rosso, P. Sismondi, and M. Sussio
- 495 A Phase II Trial of Tamoxifen, Premarin Methotrexate, and 5-Fluorouracil in Metastatic Breast Cancer
J. Allegra, T. Woodcock, J. Seeger, and D. Stevens

- 503 Neoadjuvant Chemotherapy in the Combined Modality Approach
of Locally Advanced Nonmetastatic Breast Cancer
*M. E. Lippman, S. Swain, C. S. Bagley, R. A. Sorace,
A. S. Lichter, and D. N. Danforth, Jr.*
- 517 Androgen Priming and Response to Chemotherapy in Advanced
Prostate Cancer
*A. Manni, R. J. Santen, A. E. Boucher, A. Lipton, H. Harvey,
M. Simmonds, D. White-Hershey, R. A. Gordon, T. J. Rohner,
J. Drago, J. Wettlaufer, and L. M. Glode*
- 523 *Subject Index*